- Results from the primary analysis of the ongoing phase 3 clinical trial of US biotechnology company Moderna's Covid-19 vaccine have revealed 94.1 per cent efficacy of the therapeutic in preventing symptomatic infections and severe illness, according to a peer-reviewed study. https://www.nejm.org/doi/full/10.1056/nejmoa2035389 18 comments science
Linking pages
- mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants | Scientific Reports https://www.nature.com/articles/s41598-022-06629-2 1849 comments
- Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2109522 1533 comments
- Pfizer, Moderna vaccines aren’t the same; study finds antibody differences | Ars Technica https://arstechnica.com/science/2022/03/pfizer-moderna-vaccines-spur-slightly-different-antibodies-study-finds/ 860 comments
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2101765?query=featured_home 528 comments
- Nutrients | Free Full-Text | Vitamin D3 Supplementation at 5000 IU Daily for the Prevention of Influenza-like Illness in Healthcare Workers: A Pragmatic Randomized Clinical Trial https://www.mdpi.com/2072-6643/15/1/180 238 comments
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia - The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext 144 comments
- CIMB | Free Full-Text | Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line | HTML https://www.mdpi.com/1467-3045/44/3/73/htm 99 comments
- Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months | NEJM https://www.nejm.org/doi/10.1056/nejmoa2114583 58 comments
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2108891 50 comments
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant | NEJM https://www.nejm.org/doi/full/10.1056/nejmoa2108891?query=featured_coronavirus 50 comments
- Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2200797 43 comments
- US is split between the vaccinated and unvaccinated – and deaths and hospitalizations reflect this divide https://theconversation.com/us-is-split-between-the-vaccinated-and-unvaccinated-and-deaths-and-hospitalizations-reflect-this-divide-164460 36 comments
- Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2110475 35 comments
- Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2110475?query=featured_home 35 comments
- A Bivalent Omicron-Containing Booster Vaccine against Covid-19 | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2208343 33 comments
- Novavax Is Now the Best COVID-19 Vaccine - The Atlantic https://www.theatlantic.com/health/archive/2021/06/novavax-now-best-covid-19-vaccine/619276/ 32 comments
- Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase | NEJM http://dx.doi.org/10.1056/nejmoa2113017 24 comments
- Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine | NEJM https://www.nejm.org/doi/10.1056/NEJMc2101667 23 comments
- JCM | Free Full-Text | Influence of Seasonality and Public-Health Interventions on the COVID-19 Pandemic in Northern Europe https://www.mdpi.com/2077-0383/13/2/334 19 comments
- CIMB | Free Full-Text | Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line https://www.mdpi.com/1467-3045/44/3/73/htm?s=09 16 comments
Linked pages
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2022483 1299 comments
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine | NEJM https://www.nejm.org/doi/full/10.1056/nejmoa2026920 63 comments
- Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older | NEJM http://www.nejm.org/doi/full/10.1056/nejmoa1603800?query=featured_home 7 comments
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2034577 1 comment
- Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2024671 0 comments
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2027906 0 comments
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2028436?query=featured_home 0 comments
Related searches:
Search whole site: site:www.nejm.org
Search title: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine | NEJM
See how to search.